Prelude Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Prelude Therapeutics Inc. on June 14, 2024. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol PRLD.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
The primary material event reported is the successful adoption of two proposals at the Annual Meeting:
- Election of Directors: Paul A. Friedman, M.D., and David P. Bonita, M.D., were elected as Class I Directors for three-year terms expiring at the 2027 Annual Meeting.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Director Election Results: Paul A. Friedman received 31,165,370 votes "For" with 1,762,716 "Withheld." David P. Bonita received 31,007,172 votes "For" with 1,920,914 "Withheld."
- Auditor Vote Results: The ratification of Ernst & Young LLP received 34,994,229 votes "For," 57,512 "Against," and 14,440 "Abstaining."
- Broker Non-Votes: There were 2,138,095 broker non-votes recorded for the director elections and zero for the auditor ratification.
- Signatory: The report was signed on June 18, 2024, by Bryant Lim, Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer.